The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease which is characterized by extremely complex pathogenetic mechanisms and multifactorial etiology. Some of the many pathophysiological mechanisms involved in the development of NAFLD include oxidative stress, impaire...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/24/13219 |
| _version_ | 1797503953056825344 |
|---|---|
| author | Branka Filipovic Snezana Lukic Dragana Mijac Marija Marjanovic-Haljilji Marko Vojnovic Jelena Bogdanovic Tijana Glisic Natasa Filipovic Jamal Al Kiswani Aleksandra Djokovic Suncica Kapor Slobodan Kapor Zoran Bukumiric Ana Starcevic |
| author_facet | Branka Filipovic Snezana Lukic Dragana Mijac Marija Marjanovic-Haljilji Marko Vojnovic Jelena Bogdanovic Tijana Glisic Natasa Filipovic Jamal Al Kiswani Aleksandra Djokovic Suncica Kapor Slobodan Kapor Zoran Bukumiric Ana Starcevic |
| author_sort | Branka Filipovic |
| collection | DOAJ |
| description | Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease which is characterized by extremely complex pathogenetic mechanisms and multifactorial etiology. Some of the many pathophysiological mechanisms involved in the development of NAFLD include oxidative stress, impaired mitochondrial metabolism, inflammation, gut microbiota, and interaction between the brain-liver-axis and the regulation of hepatic lipid metabolism. The new therapeutic approaches in the treatment of NAFLD are targeting some of these milestones along the pathophysiological pathway and include drugs like agonists of peroxisome proliferator-activated receptors (PPARs), glucagon-like peptide-1 (GLP-1) agonists, sodium/glucose transport protein 2 (SGLT2) inhibitors, farnesoid X receptor (FXR) agonists, probiotics, and symbiotics. Further efforts in biomedical sciences should focus on the investigation of the relationship between the microbiome, liver metabolism, and response to inflammation, systemic consequences of metabolic syndrome. |
| first_indexed | 2024-03-10T03:57:44Z |
| format | Article |
| id | doaj.art-a756701b331547748479bfa2a12f3a23 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T03:57:44Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-a756701b331547748479bfa2a12f3a232023-11-23T08:43:03ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-12-0122241321910.3390/ijms222413219The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver DiseaseBranka Filipovic0Snezana Lukic1Dragana Mijac2Marija Marjanovic-Haljilji3Marko Vojnovic4Jelena Bogdanovic5Tijana Glisic6Natasa Filipovic7Jamal Al Kiswani8Aleksandra Djokovic9Suncica Kapor10Slobodan Kapor11Zoran Bukumiric12Ana Starcevic13Faculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, SerbiaDepartment of Gastroenterology, Clinical and Hospital Center “Dr Dragisa Misovic-Dedinje”, Heroja Milana Tepica 1, 11020 Belgrade, SerbiaClinic of Gastroenterology and Hepatology, Clinical Center of Serbia, Koste Todorovica 2, 11000 Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, SerbiaDepartment of Gastroenterology, Clinical and Hospital Center “Dr Dragisa Misovic-Dedinje”, Heroja Milana Tepica 1, 11020 Belgrade, SerbiaDepartment of Gastroenterology, Clinical and Hospital Center “Dr Dragisa Misovic-Dedinje”, Heroja Milana Tepica 1, 11020 Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, SerbiaDepartment of Hematology, Clinical and Hospital Center “Dr Dragisa Misovic-Dedinje”, Heroja Milana Tepica 1, 11020 Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, SerbiaFaculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, SerbiaNon-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease which is characterized by extremely complex pathogenetic mechanisms and multifactorial etiology. Some of the many pathophysiological mechanisms involved in the development of NAFLD include oxidative stress, impaired mitochondrial metabolism, inflammation, gut microbiota, and interaction between the brain-liver-axis and the regulation of hepatic lipid metabolism. The new therapeutic approaches in the treatment of NAFLD are targeting some of these milestones along the pathophysiological pathway and include drugs like agonists of peroxisome proliferator-activated receptors (PPARs), glucagon-like peptide-1 (GLP-1) agonists, sodium/glucose transport protein 2 (SGLT2) inhibitors, farnesoid X receptor (FXR) agonists, probiotics, and symbiotics. Further efforts in biomedical sciences should focus on the investigation of the relationship between the microbiome, liver metabolism, and response to inflammation, systemic consequences of metabolic syndrome.https://www.mdpi.com/1422-0067/22/24/13219non-alcoholic fatty liver diseaselipotoxicityorganelle dysfunctiondysbiosisnew therapeutic modalities |
| spellingShingle | Branka Filipovic Snezana Lukic Dragana Mijac Marija Marjanovic-Haljilji Marko Vojnovic Jelena Bogdanovic Tijana Glisic Natasa Filipovic Jamal Al Kiswani Aleksandra Djokovic Suncica Kapor Slobodan Kapor Zoran Bukumiric Ana Starcevic The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease International Journal of Molecular Sciences non-alcoholic fatty liver disease lipotoxicity organelle dysfunction dysbiosis new therapeutic modalities |
| title | The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease |
| title_full | The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease |
| title_fullStr | The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease |
| title_full_unstemmed | The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease |
| title_short | The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease |
| title_sort | new therapeutic approaches in the treatment of non alcoholic fatty liver disease |
| topic | non-alcoholic fatty liver disease lipotoxicity organelle dysfunction dysbiosis new therapeutic modalities |
| url | https://www.mdpi.com/1422-0067/22/24/13219 |
| work_keys_str_mv | AT brankafilipovic thenewtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT snezanalukic thenewtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT draganamijac thenewtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT marijamarjanovichaljilji thenewtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT markovojnovic thenewtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT jelenabogdanovic thenewtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT tijanaglisic thenewtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT natasafilipovic thenewtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT jamalalkiswani thenewtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT aleksandradjokovic thenewtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT suncicakapor thenewtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT slobodankapor thenewtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT zoranbukumiric thenewtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT anastarcevic thenewtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT brankafilipovic newtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT snezanalukic newtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT draganamijac newtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT marijamarjanovichaljilji newtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT markovojnovic newtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT jelenabogdanovic newtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT tijanaglisic newtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT natasafilipovic newtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT jamalalkiswani newtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT aleksandradjokovic newtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT suncicakapor newtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT slobodankapor newtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT zoranbukumiric newtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease AT anastarcevic newtherapeuticapproachesinthetreatmentofnonalcoholicfattyliverdisease |